<SEC-DOCUMENT>0001628280-23-013290.txt : 20230426
<SEC-HEADER>0001628280-23-013290.hdr.sgml : 20230426
<ACCEPTANCE-DATETIME>20230426172234
ACCESSION NUMBER:		0001628280-23-013290
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20230426
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Cost Associated with Exit or Disposal Activities
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230426
DATE AS OF CHANGE:		20230426

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SANGAMO THERAPEUTICS, INC
		CENTRAL INDEX KEY:			0001001233
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				680359556
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30171
		FILM NUMBER:		23850889

	BUSINESS ADDRESS:	
		STREET 1:		7000 MARINA BLVD
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005
		BUSINESS PHONE:		5109706000

	MAIL ADDRESS:	
		STREET 1:		7000 MARINA BLVD
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANGAMO BIOSCIENCES INC
		DATE OF NAME CHANGE:	20000208
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>sgmo-20230426.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:e910dcf1-bc7b-4985-9ec4-9288f5bc8fbc,g:43bd102d-e07e-4bef-8a75-88648a1bc7f2,d:45ed14efba074848ad46c48b08c5c7d5--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>sgmo-20230426</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i2ef6b1eb8e4449539b132b573bb052e5_D20230426-20230426" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjQ1ZWQxNGVmYmEwNzQ4NDhhZDQ2YzQ4YjA4YzVjN2Q1L3NlYzo0NWVkMTRlZmJhMDc0ODQ4YWQ0NmM0OGIwOGM1YzdkNV80L2ZyYWc6NmM4NWRhOTUzNGQ3NGZjYjllODQwMmExOGExM2NmNjcvdGFibGU6MTU4Mzg3NTEzNWI0NDY0NDhkNTYwZmQxNzNlMTM3YzcvdGFibGVyYW5nZToxNTgzODc1MTM1YjQ0NjQ0OGQ1NjBmZDE3M2UxMzdjN18yLTEtMS0xLTc2NTc0_cc3b0c1a-cba3-43aa-ae5f-21fb4288f5b1">April 26, 2023</ix:nonNumeric><ix:nonNumeric contextRef="i2ef6b1eb8e4449539b132b573bb052e5_D20230426-20230426" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjQ1ZWQxNGVmYmEwNzQ4NDhhZDQ2YzQ4YjA4YzVjN2Q1L3NlYzo0NWVkMTRlZmJhMDc0ODQ4YWQ0NmM0OGIwOGM1YzdkNV80L2ZyYWc6NmM4NWRhOTUzNGQ3NGZjYjllODQwMmExOGExM2NmNjcvdGFibGU6MTU4Mzg3NTEzNWI0NDY0NDhkNTYwZmQxNzNlMTM3YzcvdGFibGVyYW5nZToxNTgzODc1MTM1YjQ0NjQ0OGQ1NjBmZDE3M2UxMzdjN18zLTEtMS0xLTc2NTc0_8be7ec93-f4c7-4304-8944-2b7107389728">0001001233</ix:nonNumeric><ix:nonNumeric contextRef="i2ef6b1eb8e4449539b132b573bb052e5_D20230426-20230426" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjQ1ZWQxNGVmYmEwNzQ4NDhhZDQ2YzQ4YjA4YzVjN2Q1L3NlYzo0NWVkMTRlZmJhMDc0ODQ4YWQ0NmM0OGIwOGM1YzdkNV80L2ZyYWc6NmM4NWRhOTUzNGQ3NGZjYjllODQwMmExOGExM2NmNjcvdGFibGU6MTU4Mzg3NTEzNWI0NDY0NDhkNTYwZmQxNzNlMTM3YzcvdGFibGVyYW5nZToxNTgzODc1MTM1YjQ0NjQ0OGQ1NjBmZDE3M2UxMzdjN180LTEtMS0xLTc2NTc0_b1039171-fdb3-4557-a0f0-0d8d129971ec">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="sgmo-20230426.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i2ef6b1eb8e4449539b132b573bb052e5_D20230426-20230426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-26</xbrli:startDate><xbrli:endDate>2023-04-26</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i45ed14efba074848ad46c48b08c5c7d5_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Washington, D.C. 20549</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%">FORM <ix:nonNumeric contextRef="i2ef6b1eb8e4449539b132b573bb052e5_D20230426-20230426" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjQ1ZWQxNGVmYmEwNzQ4NDhhZDQ2YzQ4YjA4YzVjN2Q1L3NlYzo0NWVkMTRlZmJhMDc0ODQ4YWQ0NmM0OGIwOGM1YzdkNV8xL2ZyYWc6NjBhMTExMmRiOWViNDcyZGIwODI4NDdiZWI0YmZmNTAvdGV4dHJlZ2lvbjo2MGExMTEyZGI5ZWI0NzJkYjA4Mjg0N2JlYjRiZmY1MF84Ng_ab92034e-53af-4768-8c2f-1990bba5c57e">8-K</ix:nonNumeric> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Pursuant to Section&#160;13 or 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">of the Securities Exchange Act of 1934</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="i2ef6b1eb8e4449539b132b573bb052e5_D20230426-20230426" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjQ1ZWQxNGVmYmEwNzQ4NDhhZDQ2YzQ4YjA4YzVjN2Q1L3NlYzo0NWVkMTRlZmJhMDc0ODQ4YWQ0NmM0OGIwOGM1YzdkNV8xL2ZyYWc6NjBhMTExMmRiOWViNDcyZGIwODI4NDdiZWI0YmZmNTAvdGV4dHJlZ2lvbjo2MGExMTEyZGI5ZWI0NzJkYjA4Mjg0N2JlYjRiZmY1MF8yMzA_cc3b0c1a-cba3-43aa-ae5f-21fb4288f5b1">April&#160;26, 2023</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2ef6b1eb8e4449539b132b573bb052e5_D20230426-20230426" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjQ1ZWQxNGVmYmEwNzQ4NDhhZDQ2YzQ4YjA4YzVjN2Q1L3NlYzo0NWVkMTRlZmJhMDc0ODQ4YWQ0NmM0OGIwOGM1YzdkNV8xL2ZyYWc6NjBhMTExMmRiOWViNDcyZGIwODI4NDdiZWI0YmZmNTAvdGV4dHJlZ2lvbjo2MGExMTEyZGI5ZWI0NzJkYjA4Mjg0N2JlYjRiZmY1MF8yMzc_df36b70e-615e-4128-aceb-0dab29fb4207">SANGAMO THERAPEUTICS, INC.</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Exact name of registrant as specified in its charter)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:30.571%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.571%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.574%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2ef6b1eb8e4449539b132b573bb052e5_D20230426-20230426" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjQ1ZWQxNGVmYmEwNzQ4NDhhZDQ2YzQ4YjA4YzVjN2Q1L3NlYzo0NWVkMTRlZmJhMDc0ODQ4YWQ0NmM0OGIwOGM1YzdkNV8xL2ZyYWc6NjBhMTExMmRiOWViNDcyZGIwODI4NDdiZWI0YmZmNTAvdGFibGU6OWU3NzA0MmEyNDQ0NGU3NmI4MTRlODU4M2MxMzBkNjAvdGFibGVyYW5nZTo5ZTc3MDQyYTI0NDQ0ZTc2YjgxNGU4NTgzYzEzMGQ2MF8xLTAtMS0xLTc2NTc0_ae0b99fb-245a-4b98-bac3-02121299a665">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2ef6b1eb8e4449539b132b573bb052e5_D20230426-20230426" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQ1ZWQxNGVmYmEwNzQ4NDhhZDQ2YzQ4YjA4YzVjN2Q1L3NlYzo0NWVkMTRlZmJhMDc0ODQ4YWQ0NmM0OGIwOGM1YzdkNV8xL2ZyYWc6NjBhMTExMmRiOWViNDcyZGIwODI4NDdiZWI0YmZmNTAvdGFibGU6OWU3NzA0MmEyNDQ0NGU3NmI4MTRlODU4M2MxMzBkNjAvdGFibGVyYW5nZTo5ZTc3MDQyYTI0NDQ0ZTc2YjgxNGU4NTgzYzEzMGQ2MF8xLTItMS0xLTc2NTc0_4c977872-3021-4aed-96cb-9cba7f8571cf">000-30171</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2ef6b1eb8e4449539b132b573bb052e5_D20230426-20230426" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQ1ZWQxNGVmYmEwNzQ4NDhhZDQ2YzQ4YjA4YzVjN2Q1L3NlYzo0NWVkMTRlZmJhMDc0ODQ4YWQ0NmM0OGIwOGM1YzdkNV8xL2ZyYWc6NjBhMTExMmRiOWViNDcyZGIwODI4NDdiZWI0YmZmNTAvdGFibGU6OWU3NzA0MmEyNDQ0NGU3NmI4MTRlODU4M2MxMzBkNjAvdGFibGVyYW5nZTo5ZTc3MDQyYTI0NDQ0ZTc2YjgxNGU4NTgzYzEzMGQ2MF8xLTQtMS0xLTc2NTc0_acbff352-3821-43ff-a437-3e7f0a1635ca">68-0359556</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Commission<br/>File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(IRS Employer<br/>ID Number)</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2ef6b1eb8e4449539b132b573bb052e5_D20230426-20230426" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjQ1ZWQxNGVmYmEwNzQ4NDhhZDQ2YzQ4YjA4YzVjN2Q1L3NlYzo0NWVkMTRlZmJhMDc0ODQ4YWQ0NmM0OGIwOGM1YzdkNV8xL2ZyYWc6NjBhMTExMmRiOWViNDcyZGIwODI4NDdiZWI0YmZmNTAvdGV4dHJlZ2lvbjo2MGExMTEyZGI5ZWI0NzJkYjA4Mjg0N2JlYjRiZmY1MF8yNTkx_5f1c276a-a704-4265-8d5d-42ac383e2263">7000 Marina Blvd.</ix:nonNumeric>, <ix:nonNumeric contextRef="i2ef6b1eb8e4449539b132b573bb052e5_D20230426-20230426" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjQ1ZWQxNGVmYmEwNzQ4NDhhZDQ2YzQ4YjA4YzVjN2Q1L3NlYzo0NWVkMTRlZmJhMDc0ODQ4YWQ0NmM0OGIwOGM1YzdkNV8xL2ZyYWc6NjBhMTExMmRiOWViNDcyZGIwODI4NDdiZWI0YmZmNTAvdGV4dHJlZ2lvbjo2MGExMTEyZGI5ZWI0NzJkYjA4Mjg0N2JlYjRiZmY1MF8yNTky_402948c4-85b1-4447-9221-d34e9c4cbd5b">Brisbane</ix:nonNumeric>, <ix:nonNumeric contextRef="i2ef6b1eb8e4449539b132b573bb052e5_D20230426-20230426" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjQ1ZWQxNGVmYmEwNzQ4NDhhZDQ2YzQ4YjA4YzVjN2Q1L3NlYzo0NWVkMTRlZmJhMDc0ODQ4YWQ0NmM0OGIwOGM1YzdkNV8xL2ZyYWc6NjBhMTExMmRiOWViNDcyZGIwODI4NDdiZWI0YmZmNTAvdGV4dHJlZ2lvbjo2MGExMTEyZGI5ZWI0NzJkYjA4Mjg0N2JlYjRiZmY1MF8zMjk_66564950-0896-43f7-ab16-aef097b788f3">California</ix:nonNumeric> <ix:nonNumeric contextRef="i2ef6b1eb8e4449539b132b573bb052e5_D20230426-20230426" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjQ1ZWQxNGVmYmEwNzQ4NDhhZDQ2YzQ4YjA4YzVjN2Q1L3NlYzo0NWVkMTRlZmJhMDc0ODQ4YWQ0NmM0OGIwOGM1YzdkNV8xL2ZyYWc6NjBhMTExMmRiOWViNDcyZGIwODI4NDdiZWI0YmZmNTAvdGV4dHJlZ2lvbjo2MGExMTEyZGI5ZWI0NzJkYjA4Mjg0N2JlYjRiZmY1MF8yNTkz_42b67ebf-b6a0-4f46-b68e-4282c724dc52">94005</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of principal executive offices) (Zip Code)</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonNumeric contextRef="i2ef6b1eb8e4449539b132b573bb052e5_D20230426-20230426" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjQ1ZWQxNGVmYmEwNzQ4NDhhZDQ2YzQ4YjA4YzVjN2Q1L3NlYzo0NWVkMTRlZmJhMDc0ODQ4YWQ0NmM0OGIwOGM1YzdkNV8xL2ZyYWc6NjBhMTExMmRiOWViNDcyZGIwODI4NDdiZWI0YmZmNTAvdGV4dHJlZ2lvbjo2MGExMTEyZGI5ZWI0NzJkYjA4Mjg0N2JlYjRiZmY1MF8zOTI_21d6ea38-d4af-4afc-915e-e0a939cfea0d">510</ix:nonNumeric>) <ix:nonNumeric contextRef="i2ef6b1eb8e4449539b132b573bb052e5_D20230426-20230426" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQ1ZWQxNGVmYmEwNzQ4NDhhZDQ2YzQ4YjA4YzVjN2Q1L3NlYzo0NWVkMTRlZmJhMDc0ODQ4YWQ0NmM0OGIwOGM1YzdkNV8xL2ZyYWc6NjBhMTExMmRiOWViNDcyZGIwODI4NDdiZWI0YmZmNTAvdGV4dHJlZ2lvbjo2MGExMTEyZGI5ZWI0NzJkYjA4Mjg0N2JlYjRiZmY1MF8zOTY_203556b1-9b99-45e1-94b0-bb513e081f8a">970-6000</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Registrant&#8217;s telephone number, including area code)&#160;</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Not Applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Former Name or Former Address, if Changed Since Last Report)&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.019%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2ef6b1eb8e4449539b132b573bb052e5_D20230426-20230426" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjQ1ZWQxNGVmYmEwNzQ4NDhhZDQ2YzQ4YjA4YzVjN2Q1L3NlYzo0NWVkMTRlZmJhMDc0ODQ4YWQ0NmM0OGIwOGM1YzdkNV8xL2ZyYWc6NjBhMTExMmRiOWViNDcyZGIwODI4NDdiZWI0YmZmNTAvdGFibGU6N2NlZTRiNGMzZGUwNDMzMmEwNjJlYjRhMzYwMjU2NzgvdGFibGVyYW5nZTo3Y2VlNGI0YzNkZTA0MzMyYTA2MmViNGEzNjAyNTY3OF8wLTAtMS0xLTc2NTc0_65c6df50-2516-48a8-835c-3b571bf6c60a">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.019%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2ef6b1eb8e4449539b132b573bb052e5_D20230426-20230426" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjQ1ZWQxNGVmYmEwNzQ4NDhhZDQ2YzQ4YjA4YzVjN2Q1L3NlYzo0NWVkMTRlZmJhMDc0ODQ4YWQ0NmM0OGIwOGM1YzdkNV8xL2ZyYWc6NjBhMTExMmRiOWViNDcyZGIwODI4NDdiZWI0YmZmNTAvdGFibGU6YWVjOGZkYjRiNTEyNGEzZjk5OGNlOTU5MjQ1ZmNmZWQvdGFibGVyYW5nZTphZWM4ZmRiNGI1MTI0YTNmOTk4Y2U5NTkyNDVmY2ZlZF8wLTAtMS0xLTc2NTc0_f078855f-05f6-4a3d-acb8-a4bd43a93e9d">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"></td><td style="width:6.086%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2ef6b1eb8e4449539b132b573bb052e5_D20230426-20230426" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjQ1ZWQxNGVmYmEwNzQ4NDhhZDQ2YzQ4YjA4YzVjN2Q1L3NlYzo0NWVkMTRlZmJhMDc0ODQ4YWQ0NmM0OGIwOGM1YzdkNV8xL2ZyYWc6NjBhMTExMmRiOWViNDcyZGIwODI4NDdiZWI0YmZmNTAvdGFibGU6ZDRhZDgyNjg3YWRlNDZhNzg4OGFiYmNiOGRlODQ0NGMvdGFibGVyYW5nZTpkNGFkODI2ODdhZGU0NmE3ODg4YWJiY2I4ZGU4NDQ0Y18wLTAtMS0xLTc2NTc0_9b4766bf-b5e3-4361-ab68-6111297cc7d8">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:6.119%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.681%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2ef6b1eb8e4449539b132b573bb052e5_D20230426-20230426" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjQ1ZWQxNGVmYmEwNzQ4NDhhZDQ2YzQ4YjA4YzVjN2Q1L3NlYzo0NWVkMTRlZmJhMDc0ODQ4YWQ0NmM0OGIwOGM1YzdkNV8xL2ZyYWc6NjBhMTExMmRiOWViNDcyZGIwODI4NDdiZWI0YmZmNTAvdGFibGU6OGMzNDNiZGU5NDhhNDBkZWFjNzI3MmQ4N2UzOGRhNjkvdGFibGVyYW5nZTo4YzM0M2JkZTk0OGE0MGRlYWM3MjcyZDg3ZTM4ZGE2OV8wLTAtMS0xLTc2NTc0_5949e3ef-eaaa-449f-b5cb-56c288d7bf6e">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities registered pursuant to Section&#160;12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:30.571%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.571%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.574%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2ef6b1eb8e4449539b132b573bb052e5_D20230426-20230426" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjQ1ZWQxNGVmYmEwNzQ4NDhhZDQ2YzQ4YjA4YzVjN2Q1L3NlYzo0NWVkMTRlZmJhMDc0ODQ4YWQ0NmM0OGIwOGM1YzdkNV8xL2ZyYWc6NjBhMTExMmRiOWViNDcyZGIwODI4NDdiZWI0YmZmNTAvdGFibGU6MTE2Y2FjNmVlNDZjNDE0NGFhODZhMDcxMzg5ZmQzMzUvdGFibGVyYW5nZToxMTZjYWM2ZWU0NmM0MTQ0YWE4NmEwNzEzODlmZDMzNV8yLTAtMS0xLTc2NTc0_769a715d-a035-401f-946e-0c9ccaead85c">Common Stock, $0.01 par value per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2ef6b1eb8e4449539b132b573bb052e5_D20230426-20230426" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjQ1ZWQxNGVmYmEwNzQ4NDhhZDQ2YzQ4YjA4YzVjN2Q1L3NlYzo0NWVkMTRlZmJhMDc0ODQ4YWQ0NmM0OGIwOGM1YzdkNV8xL2ZyYWc6NjBhMTExMmRiOWViNDcyZGIwODI4NDdiZWI0YmZmNTAvdGFibGU6MTE2Y2FjNmVlNDZjNDE0NGFhODZhMDcxMzg5ZmQzMzUvdGFibGVyYW5nZToxMTZjYWM2ZWU0NmM0MTQ0YWE4NmEwNzEzODlmZDMzNV8yLTItMS0xLTc2NTc0_6afa7108-1c80-4612-99a9-3978666afea8">SGMO</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2ef6b1eb8e4449539b132b573bb052e5_D20230426-20230426" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjQ1ZWQxNGVmYmEwNzQ4NDhhZDQ2YzQ4YjA4YzVjN2Q1L3NlYzo0NWVkMTRlZmJhMDc0ODQ4YWQ0NmM0OGIwOGM1YzdkNV8xL2ZyYWc6NjBhMTExMmRiOWViNDcyZGIwODI4NDdiZWI0YmZmNTAvdGFibGU6MTE2Y2FjNmVlNDZjNDE0NGFhODZhMDcxMzg5ZmQzMzUvdGFibGVyYW5nZToxMTZjYWM2ZWU0NmM0MTQ0YWE4NmEwNzEzODlmZDMzNV8yLTQtMS0xLTc2NTc0_30713595-e08d-462b-8191-7c944df41bfd">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#160;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#160;240.12b-2 of this chapter). </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2ef6b1eb8e4449539b132b573bb052e5_D20230426-20230426" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjQ1ZWQxNGVmYmEwNzQ4NDhhZDQ2YzQ4YjA4YzVjN2Q1L3NlYzo0NWVkMTRlZmJhMDc0ODQ4YWQ0NmM0OGIwOGM1YzdkNV8xL2ZyYWc6NjBhMTExMmRiOWViNDcyZGIwODI4NDdiZWI0YmZmNTAvdGV4dHJlZ2lvbjo2MGExMTEyZGI5ZWI0NzJkYjA4Mjg0N2JlYjRiZmY1MF8xMDQz_a51f92be-525b-4cd7-8772-83c2fd635c8e">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div><div style="margin-top:10pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.02 Results of Operations and Financial Condition.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April&#160;26, 2023, Sangamo Therapeutics, Inc. (&#8220;Sangamo&#8221;) issued a press release announcing preliminary financial results for the quarter ended March 31, 2023 (the &#8220;Press Release&#8221;).</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A copy of the Press Release is furnished hereto as Exhibit 99.1 and is incorporated by reference herein. The information contained in this Item 2.02 and in the Press Release furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the Press Release furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the Securities and Exchange Commission (the &#8220;SEC&#8221;) made by Sangamo whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.05 Costs Associated with Exit or Disposal Activities.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 10, 2023, the Board of Directors of Sangamo approved a restructuring of operations and a corresponding reduction in workforce, designed to reduce costs and increase focus on its three key strategic priorities of (a) its pre-clinical neurology disease epigenetic regulation portfolio, including its Nav 1.7 and prion disease programs, (b) preparations for a potential Phase 3 trial of isaralgagene civaparvovec, its gene therapy to treat Fabry disease and (c) the Phase 1/2 STEADFAST study evaluating TX200, its wholly owned autologous CAR-Treg cell therapy to treat patients receiving an HLA-A2 mismatched kidney from a living donor. Sangamo notified employees affected by the reduction in workforce on April 26, 2023. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the restructuring, Sangamo expects to significantly reduce its internal manufacturing and allogeneic research footprints in California. Sangamo expects the restructuring to result in the elimination of approximately 120 roles in the United States, or approximately 27% of its United States workforce. Sangamo estimates that it will incur approximately $5 million to $7 million in cash-based expenses related to employee severance and notice period payments, benefits and related restructuring costs. Sangamo expects that the majority of the restructuring charges will be incurred in the second quarter of 2023 and that the execution of the restructuring will be substantially complete by the end of the third quarter of 2024. Sangamo may also incur other charges or cash expenditures not currently contemplated due to events that may occur as a result of, or associated with, the restructuring.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with Sangamo&#8217;s restructuring and corresponding reduction in workforce, the employment of R. Andrew Ramelmeier, Ph.D., Executive Vice President, Technical Operations, will terminate effective as of July 10, 2023. In connection with the termination of his employment, pursuant to the Sangamo Amended and Restated Executive Severance Plan, a copy of which is attached as Exhibit&#160;10.20 to Sangamo&#8217;s Annual Report on Form&#160;10-K for the period ended on December 31, 2018, Dr.&#160;Ramelmeier is entitled to certain severance benefits in exchange for the execution of a general settlement and release agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Statements contained in this Current Report on Form 8-K regarding matters that are not historical facts are &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;may,&#8221; &#8220;will&#8221; and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These statements include those related to the costs, timing and financial impact of the restructuring; Sangamo&#8217;s focus on its key strategic priorities; and other statements that are not historical fact. Because such statements deal with future events and are based on Sangamo&#8217;s current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements of the Company could differ materially from those described in or implied by the statements in this Current Report on Form 8-K. These forward-looking statements are subject to risks and uncertainties, including, without limitation, risks and uncertainties associated with: impediments to Sangamo&#8217;s ability to execute the restructuring as currently contemplated; the actual charges associated with the restructuring being higher than anticipated or changes to the assumptions on which the estimated charges associated with the restructuring are based; Sangamo&#8217;s ability to achieve projected cost savings in connection with the restructuring; unintended consequences from the restructuring that impact Sangamo&#8217;s business; and other risks and uncertainties affecting Sangamo, including those discussed in the section titled &#8220;Risk Factors&#8221; in Sangamo&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022, as supplemented by Sangamo&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 to be filed with the SEC and subsequent filings and reports that Sangamo makes from time to time with the SEC. Except as required by law, Sangamo assumes no obligation to update these forward-looking statements, or to update the reasons if actual results differ materially from those anticipated in the forward-looking statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9.01 Financial Statements and Exhibits.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exhibits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.543%"><tr><td style="width:1.0%"></td><td style="width:12.170%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.165%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.901%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.693%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit<br/>No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit-99120230426.htm">Press Release regarding </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit-99120230426.htm">preliminary </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit-99120230426.htm">financial results dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit-99120230426.htm">April 26,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit-99120230426.htm"> 2023</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.990%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SANGAMO THERAPEUTICS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: April 26, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ SCOTT B. WILLOUGHBY</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scott B. Willoughby</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President, General Counsel and Corporate Secretary</span></td></tr></table></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit-99120230426.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="id58107b843b4425e97966b6449ec3c33_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="padding-left:432pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div><img alt="logo.gif" src="logo.gif" style="height:100px;margin-bottom:5pt;vertical-align:text-bottom;width:300px"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SANGAMO THERAPEUTICS ANNOUNCES STRATEGIC UPDATE AND REPORTS </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PRELIMINARY FIRST QUARTER 2023 FINANCIAL RESULTS </font></div><div><font><br></font></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Strong clinical momentum continues in Phase 1&#47;2 STAAR study in Fabry disease with 20 patients dosed in total.</font></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Dosed third patient in cohort 1 of Phase 1&#47;2 CAR-Treg STEADFAST study for TX200 in HLA A2 mismatched kidney transplantation. </font></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Unveiled Nav1.7 target to treat chronic neuropathic pain as flagship program of wholly owned neurology epigenetic regulation pipeline, with IND submission expected in 2024. </font></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Announced strategic pipeline prioritization and corporate restructuring, including US workforce reduction of approximately 27%.</font></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Conference call and webcast scheduled for Thursday, April 27 at 8&#58;30 a.m. Eastern Time.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Brisbane, California, April 26, 2023</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Sangamo Therapeutics, Inc. (Nasdaq&#58; SGMO), a genomic medicines company, today announced recent business highlights, including a strategic pipeline prioritization and restructuring, and reported certain preliminary first quarter 2023 financial results.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;This quarter, Sangamo continued to advance its clinical and pre-clinical pipeline. Our Phase 1&#47;2 Fabry study continues to enroll and dose patients, alongside preparations for a potential Phase 3 trial expected to commence by the end of 2023. We successfully dosed the third patient with TX200, our CAR-Treg therapy in kidney transplantation, and received positive regulatory feedback from the first two European authorities required to accelerate the dose escalation. We are also excited to unveil Nav 1.7 as the prioritized target in our wholly owned neurology epigenetic regulation pipeline,&#8221; said Sandy Macrae, Chief Executive Officer of Sangamo. &#8220;Today&#8217;s environment necessitates careful choices when deciding how many programs to take forward at once. We are therefore announcing a sharpened strategic focus, prioritizing our investments in our most promising programs. This has led to difficult, but necessary, decisions to step away from certain pre-clinical assets, shrink parts of our infrastructure and redeploy investments towards realizing the full potential of what we believe are our most valuable programs.&#8221;</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The restructuring announced today is the result of a strategic decision to increase focus on three key areas&#58; Nav 1.7 and Prion as cornerstones to the neurology epigenetic regulation portfolio&#59; Fabry Phase 3 readiness&#59; and the TX200 CAR-Treg clinical study, alongside a broader rightsizing of resources and investments across the company. Additionally, Sangamo expects to significantly reduce its internal manufacturing and allogeneic research footprints in California. As a result of this restructuring, Sangamo is reducing its US workforce by approximately 27%, or approximately 120 roles. These actions are in addition to the previously announced portfolio prioritization which resulted in the decision to seek a partner for our sickle cell disease program. In addition, R. Andrew Ramelmeier, Ph.D., Executive Vice President, Technical Operations will be leaving the company on July 10, 2023. Phillip Ramsey, currently serving as Vice President, Technical Development, has been appointed as Head of Technical Operations effective May 29, 2023.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The restructuring plus other planned cost reduction initiatives are expected to result in annualized savings of approximately $31&#160;million. Sangamo believes its available cash, cash equivalents and marketable securities as of March 31, 2023, in combination with the other expected cost reductions, will be sufficient to fund its planned operations for at least the next 12 months. Sangamo expects to incur approximately $5 million - $7 million in one-time restructuring costs in the second and third quarters of 2023. Sangamo is assessing ways to further reduce annual operating expenses, consistent with the prioritized objectives and progress of the company. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;I am grateful to all our employees for their commitment to Sangamo and dedication to patients, and have special gratitude to those who are leaving for all they have done to advance our mission. Additionally, I would like to personally thank Andy for the passion, dedication and leadership he has brought to Sangamo. He leaves a great legacy of technical excellence and I wish him well in the future.&#8221;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Business Highlights</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Neurology Epigenetic Regulation Programs &#8211; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unveiled Nav1.7 program to treat chronic neuropathic pain as flagship program in prioritized wholly owned neurology pipeline&#59; made strategic decision to pause further development of other pre-clinical programs following conclusion of collaborations with Biogen and Novartis. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Announced Nav1.7 to treat chronic neuropathic pain as flagship program in Sangamo&#8217;s newly prioritized wholly owned neurology pipeline, with an IND submission expected in 2024. First data from this program expected to be published via a platform presentation at the upcoming American Society for Cell and Gene Therapy (ASGCT) 26th Annual Meeting in Los Angeles in May 2023.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Advanced wholly owned prion disease program, with an IND submission anticipated in 2025.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continued to advance identification and selection of engineered AAV capsids for enhanced central nervous system delivery.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Following a strategic portfolio evaluation, decided to pause further development of programs previously partnered with Biogen and Novartis, pending the identification of a suitable capsid for delivery for those specific indications. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fabry disease &#8211; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dosed three additional patients in Phase 1&#47;2 STAAR study&#59; advancing Phase 3 trial design planning in anticipation of FDA meeting in the summer&#59; expect to begin pivotal trial by end of 2023.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Dosed three additional patients in the dose expansion phase of the Phase 1&#47;2 STAAR study evaluating isaralgagene civaparvovec, our wholly owned gene therapy product for the treatment of Fabry disease, for a total of 20 patients dosed to date. We expect dosing to conclude by the end of 2023.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Plan to meet with the FDA on proposed Phase 3 study design in the summer and anticipate commencement of the pivotal trial in the second half of 2023, with dosing of the first patient expected to start as early as the first part of 2024.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Renal Transplant Rejection &#8211; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dosed third patient in cohort 1&#59; preparations for higher dose cohort underway&#59; efforts to accelerate dose escalation advancing through regulatory reviews&#59; prioritizing near-term autologous portfolio, resulting in the relocation of allogeneic development and manufacturing activities.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"> </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Dosed third patient in cohort 1 in the Phase 1&#47;2 STEADFAST study evaluating TX200, our wholly owned autologous CAR-Treg cell therapy treating patients receiving an HLA-A2 mismatched kidney from a living donor. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The product candidate continues to be generally well tolerated in all three patients dosed to date. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Received positive regulatory feedback for accelerated dose escalation protocol from two European agencies to date.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Plan to share initial data from cohort 1 by the end of 2023.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Intend to prioritize near-term autologous portfolio, resulting in decision to transition all remaining allogeneic research activities from Sangamo US to Sangamo France, and to cease cell therapy manufacturing in California.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hemophilia A (Pfizer) &#8211; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dosing of patients in Phase 3 AFFINE trial to support primary analysis complete&#59; pivotal data read-out expected in mid-2024&#59; BLA and MAA submissions anticipated in second half of 2024.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Dosing of patients to support primary analysis is complete in the Phase 3 AFFINE trial of giroctocogene fitelparvovec, an investigational gene therapy we are developing with Pfizer for patients with moderately severe to severe hemophilia&#160;A. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A pivotal readout is expected in mid-2024, with Pfizer anticipating BLA and MAA submissions in the second half of 2024.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">American Society of Gene and Cell Therapy (ASGCT) 26</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> Annual Meeting &#8211; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">14 Sangamo abstracts accepted.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A total of 14 Sangamo abstracts were accepted for presentation at ASGCT on May 16-20, 2023, in Los Angeles, California, including pre-clinical updates from our prioritized neurology programs Nav 1.7 and Prion, innovations in our epigenetic regulation platform and advances in our AAV capsid engineering program.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preliminary First Quarter 2023 Financial Results</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo is in the process of completing its customary quarter-end close and review procedures, including the evaluation of non-cash charges related to impairment of long-lived assets, as of and for the quarter ended March 31, 2023, and the final </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">results for this period could materially differ from the preliminary expected results disclosed in this press release. Sangamo&#8217;s full first quarter 2023 financial results will be reflected in a Quarterly Report on Form 10-Q which is expected to be filed no later than May 10, 2023. The financial performance measures presented in this press release for the first quarter of 2023 are forward-looking statements, preliminary estimates and unaudited, based on management&#8217;s initial review of the information presented, and are thus inherently uncertain and subject to change as Sangamo completes its end-of-period reporting process and related activities for the first quarter of 2023. During the course of the review of Sangamo&#8217;s condensed consolidated financial statements and related notes as of and for the quarter ended March 31, 2023, Sangamo&#8217;s independent registered public accountants may identify items that could cause final reported results to be materially different from the preliminary estimates presented herein. Additional information and disclosures would be required for a more complete understanding of Sangamo&#8217;s financial position and results of operations as of and for the quarter ended March 31, 2023. Accordingly, undue reliance should not be placed on this preliminary information.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues for the first quarter ended March 31, 2023, are estimated to be approximately $158.0 million, compared to $28.2 million for the same period in 2022.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated increase of $129.8 million in revenues is primarily attributable to an increase of $121.1 million in revenue relating to our collaboration agreement with Biogen, mainly due to the impact of termination related contract modification, and an increase of $6.0 million in revenue relating to our collaboration agreement with Kite, mainly due to a reduction in the estimated project costs, which resulted in an adjustment to the measure of proportional cumulative performance. </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Expenses</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating expenses on a GAAP basis for the first quarter ended March 31, 2023, are estimated to be in the range of $120 million to $140 million, compared to $73.5 million for the same period in 2022.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total estimated operating expenses on a GAAP basis for the quarter included certain non-cash charges such as impairment of goodwill of $38.1 million, and impairment of long-lived assets of up to $20 million. These estimated charges are a result of the termination of our collaboration agreements with Biogen and Novartis, a sustained decline in our stock price and related market capitalization and a general decline in equity values in the biotechnology industry.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash, Cash Equivalents and Marketable Securities</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and marketable securities as of March 31, 2023 were $241.0 million, compared to $307.5 million as of December 31, 2022.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo believes its available cash, cash equivalents and marketable securities as of March 31, 2023, in combination with the other expected cost reductions, will be sufficient to fund its planned operations for at least the next 12 months.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Guidance for 2023 Updated</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In line with the business announcements outlined, we are revising our full-year operating expense guidance as follows&#58;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">GAAP operating expenses, including goodwill and long-lived assets impairment charges and stock-based compensation expense, are estimated to be in the range of approximately $315 million to $335 million (updated on April 26, 2023). The previous GAAP operating expenses guidance provided on February 22, 2023 was in the range of approximately $310 million to $330 million. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Non-GAAP operating expenses are estimated to be in the range of approximately $240 million to $260 million (updated on April 26, 2023). Estimated non-GAAP operating expenses exclude impairment of goodwill of $38 million, impairment of long-lived assets of up to $20 million and stock-based compensation expense of $35 million. The previous non-GAAP operating expenses guidance provided on February 22, 2023 was in the range of approximately $275 million to $295 million.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Upcoming Events</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo plans to participate in the following events&#58;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Scientific &#47; Medical Conferences</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ASGCT 26</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Annual Meeting, Los Angeles, California, May 16-20, 2023</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investor Conferences</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">2023 Bank of America Global Healthcare Conference, May 9, 2023</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">2023 RBC Global Healthcare Conference, May 17, 2023</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Annual Barclays Gene Editing and Gene Therapy Summit, May 24, 2023</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Stifel 2023 Tailoring Genes&#58; Genetic Medicines Day, May 30, 2023</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Jefferies Global Healthcare Conference, June 8, 2023</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">2023 Wedbush Pacgrow Healthcare Conference, August 8-9, 2023</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">2023 Wells Fargo Healthcare Conference, September 6-8, 2023</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Access links for available webcasts for these investor conferences will be available on the Sangamo website in the Investors and Media section under</font><font style="color:#0a2299;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Events</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Available materials will be found on the Sangamo website after the event under</font><font style="color:#0a2299;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Presentations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Conference Call to Discuss Business Updates and Preliminary First Quarter 2023 Results</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Sangamo management team will discuss these business updates and preliminary results on a conference call tomorrow, Thursday, April 27, 2023, at 8&#58;30&#160;a.m. Eastern Time.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Participants should register for, and access, the call using</font><font style="color:#0a2299;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> this link</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. While not required, it is recommended you join 10 minutes prior to the event start. Once registered, participants will be given the option to either dial into the call with the number and unique passcode provided or to use the dial-out option to connect their phone instantly.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An updated corporate presentation is available in the Investors and Media section under</font><font style="color:#0a2299;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Presentations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The link to access the live webcast can also be found on the Sangamo website in the Investors and Media section under</font><font style="color:#0a2299;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Events</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. A replay will be available following the conference call, accessible at the same link.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Sangamo Therapeutics</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo Therapeutics is a clinical-stage biopharmaceutical company with a robust genomic medicines pipeline. Using ground-breaking science, including our proprietary zinc finger genome engineering technology and manufacturing expertise, Sangamo aims to create new genomic medicines for patients suffering from diseases for which existing treatment options are inadequate or currently don&#8217;t exist. To learn more, visit </font><font style="color:#0a2299;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">www.sangamo.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and connect with us on</font><font style="color:#0a2299;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> LinkedIn</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and</font><font style="color:#0a2299;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Twitter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forward-Looking Statements </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This press release contains forward-looking statements regarding our current expectations. These forward-looking statements include, without limitation, statements relating to&#58; our preliminary estimated operating results for the quarter ended March 31, 2023, the therapeutic and commercial potential of our product candidates, the anticipated plans and timelines of Sangamo and our collaborators for screening, enrolling and dosing patients in and conducting our ongoing and potential future clinical trials and presenting clinical data from our clinical trials, including expectations regarding the conclusion of dosing in our Phase 1&#47;2 STAAR study, preparations and plans for patient dosing in the STEADFAST study and the potential for acceleration of the study timeline, the anticipated advancement of our product candidates to late-stage development, including potential future Phase 3 trials of isaralgagene civaparvovec and the timing thereof, the availability and presentation of data from the Phase 3 AFFINE trial, and plans for a BLA and MAA submission for giroctocogene fitelparvovec, expectations regarding advancement of our preclinical neurology programs, including announcement of data from, and anticipated IND submissions related to, such programs, the potential for a partner for our sickle cell disease program&#59; expectations concerning our strategic prioritization and restructuring, including plans to reduce our manufacturing and allogenic research footprints and the expected charges and cost savings associated with such restructuring, future cost reductions, our expected cash runway, our 2023 financial guidance related to GAAP and non-GAAP total operating expenses and stock-based compensation, our plans to participate in industry and investor conferences, and other statements that are not historical fact. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to impediments to adjustments to Sangamo&#8217;s preliminary measures of financial performance resulting from, among other things, the completion of Sangamo&#8217;s financial close procedures&#59; Sangamo&#8217;s ability to execute its strategic prioritization and restructuring as currently contemplated&#59; the actual charges associated with the restructuring being higher than anticipated or changes to the assumptions on which the estimated charges associated with the restructuring are based&#59; Sangamo&#8217;s ability to achieve projected cost savings in connection with the restructuring and to further reduce operating expenses&#59; unintended consequences from the restructuring that impact Sangamo&#8217;s business&#59; the effects of macroeconomic factors or financial challenges, including as a result of the ongoing conflict between Russia and Ukraine, the COVID-19 pandemic and current or potential future bank failures, on the global business environment, healthcare systems and business and operations of Sangamo and our collaborators, including the initiation and operation of clinical trials&#59; the research and development process, including the enrollment, operation and </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">results of clinical trials and the presentation of clinical data&#59; the impacts of clinical trial delays, pauses and holds on clinical trial timelines and commercialization of product candidates&#59; the uncertain timing and unpredictable nature of clinical trial results, including the risk that therapeutic effects in the Phase 3 AFFINE trial will not be durable in patients as well as the risk that the therapeutic effects observed in the latest preliminary clinical data from the Phase 1&#47;2 STAAR study, including data from kidney biopsies, and the Phase 1&#47;2 PRECIZN-1 study will not be durable in patients and that final clinical trial data from the study will not validate the safety and efficacy of isaralgagene civaparvovec, and that the patients withdrawn from ERT will remain off ERT&#59; the unpredictable regulatory approval process for product candidates across multiple regulatory authorities&#59; reliance on results of early clinical trials, which results are not necessarily predictive of future clinical trial results, including the results of any Phase 3 trial of our product candidates&#59; our limited experience manufacturing biopharmaceutical products, including the risks that we may be unable to maintain compliant manufacturing facilities, build additional facilities and manufacture our product candidates as intended&#59; the potential for technological developments that obviate technologies used by Sangamo&#59; our lack of capital resources to fully develop, obtain regulatory approval for and commercialize our product candidates, and our related need for substantial additional funding to execute our operating plan and to continue to operate as a going concern&#59; our reliance on collaborators and our potential inability to secure additional collaborations, including for our sickle cell disease program&#59; and our ability to achieve expected future financial performance.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">There can be no assurance that we and our collaborators will be able to develop commercially viable products. Actual results may differ materially from those projected in these forward-looking statements due to the risks and uncertainties described above and other risks and uncertainties that exist in the operations and business environments of Sangamo and our collaborators. These risks and uncertainties are described more fully in our Securities and Exchange Commission, or SEC, filings and reports, including in our Annual Report on Form 10-K for the year ended December 31, 2022, as supplemented by our Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 to be filed with the SEC, and future filings and reports that Sangamo makes from time to time with the SEC. Forward-looking statements contained in this announcement are made as of this date, and we undertake no duty to update such information except as required under applicable law.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-GAAP Financial Measures</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">To supplement our financial guidance presented in accordance with GAAP, we present non-GAAP total operating expenses financial guidance, which exclude stock-based compensation expense and impairment of goodwill and long-lived assets from GAAP total operating expenses. We believe that these non-GAAP financial measures, when considered together with our financial information prepared in accordance with GAAP, can enhance investors&#8217; and analysts&#8217; ability to meaningfully compare our results from period to period and to our forward-looking guidance, and to identify operating trends in our business. We have excluded stock-based compensation expense because it is a non-cash expense that may vary significantly from period to period as a result of changes not directly or immediately related to the operational performance for the periods presented, and we have excluded impairment of goodwill and long-lived assets to facilitate a more meaningful evaluation of our current operating performance and comparisons to our operating performance in other periods. These non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP financial information, to more fully understand our business.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contact&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Investor Relations &#38; Media Inquiries </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Louise Wilkie&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ir&#64;sangamo.com </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">media&#64;sangamo.com </font></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>sgmo-20230426.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:e910dcf1-bc7b-4985-9ec4-9288f5bc8fbc,g:43bd102d-e07e-4bef-8a75-88648a1bc7f2-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sgmo="http://www.sangamo.com/20230426" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.sangamo.com/20230426">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20230426_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20230426_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPageCoverPage" roleURI="http://www.sangamo.com/role/CoverPageCoverPage">
        <link:definition>0000001 - Document - Cover Page Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>sgmo-20230426_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:e910dcf1-bc7b-4985-9ec4-9288f5bc8fbc,g:43bd102d-e07e-4bef-8a75-88648a1bc7f2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityCentralIndexKey_eb68cb5c-7356-4231-ac79-0e303c9f0a00_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_68945934-a5f9-4026-9a40-16b82e4d6bcd_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_59b0873c-cda0-4d41-95c8-6e034f2b99ab_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_88f5a7d4-a544-46ae-be36-f531ee01e465_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_a6d20b31-f509-4d2f-82cb-3fd7c0e90b90_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_06b9d87d-3377-46a7-836a-dd8a24217de2_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_67a40171-85ae-4d03-9d35-796ce1827614_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_16cd033a-8cf5-4d0c-849e-3adefd6c6e0f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_0f463628-93b7-4726-85a8-248d77954879_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_8a2dcee2-3060-4748-950c-dccd2a6f6599_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_116d6ce0-e653-43b5-b225-1a7e69d47630_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_f64376d4-7df4-4f95-adbd-9a7cf929d395_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_b12bd6d3-0f79-4402-acdb-34b0296b076b_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_d4cbd242-35b3-4076-b3a0-c6a3234cb032_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_ab97e2e3-f0a6-42a0-bb9d-c859cc799d65_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_51ece1ff-6355-46bf-86af-5ef4a2eea54f_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_8dd38f11-efc2-4f45-85f1-fbe1d93fa3bf_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_6cac1e32-7df4-4d59-ab4e-3cc43e302983_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_51ca4b89-3a1e-4abf-8b9b-e52f815d00ec_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_d969c1c2-29b9-4299-a41b-b4cd99c3d0f0_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_58a76979-49c9-4b2c-9577-225c11ef294c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_43ba55d3-74c7-42f9-aabb-9d53d6efa465_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_9798c07d-5758-4ae9-9846-4c1b8d18ac6a_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>sgmo-20230426_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:e910dcf1-bc7b-4985-9ec4-9288f5bc8fbc,g:43bd102d-e07e-4bef-8a75-88648a1bc7f2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.sangamo.com/role/CoverPageCoverPage" xlink:type="simple" xlink:href="sgmo-20230426.xsd#CoverPageCoverPage"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CoverPageCoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_ab13e032-3368-44cd-85e6-ebb48d26940c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_b602065b-fc17-4c8e-8f02-de9f3e614130" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab13e032-3368-44cd-85e6-ebb48d26940c" xlink:to="loc_dei_DocumentType_b602065b-fc17-4c8e-8f02-de9f3e614130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_824b4f7f-03b7-4fe6-b23d-bf36d22d7d5b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab13e032-3368-44cd-85e6-ebb48d26940c" xlink:to="loc_dei_DocumentPeriodEndDate_824b4f7f-03b7-4fe6-b23d-bf36d22d7d5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_f84e2f14-4f19-4fdb-9050-852e9421d217" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab13e032-3368-44cd-85e6-ebb48d26940c" xlink:to="loc_dei_EntityRegistrantName_f84e2f14-4f19-4fdb-9050-852e9421d217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_0aa77f07-78eb-4d38-87f0-35f1ade29077" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab13e032-3368-44cd-85e6-ebb48d26940c" xlink:to="loc_dei_EntityIncorporationStateCountryCode_0aa77f07-78eb-4d38-87f0-35f1ade29077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_af0866c5-c6bd-4039-ba9b-2a6c5c476a4b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab13e032-3368-44cd-85e6-ebb48d26940c" xlink:to="loc_dei_EntityFileNumber_af0866c5-c6bd-4039-ba9b-2a6c5c476a4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_a6c40d20-b266-48fe-913e-8cab0c649024" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab13e032-3368-44cd-85e6-ebb48d26940c" xlink:to="loc_dei_EntityTaxIdentificationNumber_a6c40d20-b266-48fe-913e-8cab0c649024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_48c624da-b55c-4148-8573-173de3cb0226" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab13e032-3368-44cd-85e6-ebb48d26940c" xlink:to="loc_dei_EntityAddressAddressLine1_48c624da-b55c-4148-8573-173de3cb0226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_79ad81bb-9a07-48ba-a9b9-fa6b09dd1f40" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab13e032-3368-44cd-85e6-ebb48d26940c" xlink:to="loc_dei_EntityAddressCityOrTown_79ad81bb-9a07-48ba-a9b9-fa6b09dd1f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_dbcabdef-0552-49d7-94df-cdbf6f3b216e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab13e032-3368-44cd-85e6-ebb48d26940c" xlink:to="loc_dei_EntityAddressStateOrProvince_dbcabdef-0552-49d7-94df-cdbf6f3b216e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_626dad11-13b9-42fa-8f56-98882b076348" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab13e032-3368-44cd-85e6-ebb48d26940c" xlink:to="loc_dei_EntityAddressPostalZipCode_626dad11-13b9-42fa-8f56-98882b076348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_9595bf95-f842-474c-94d6-f784e2da6c3f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab13e032-3368-44cd-85e6-ebb48d26940c" xlink:to="loc_dei_CityAreaCode_9595bf95-f842-474c-94d6-f784e2da6c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_36d58dbb-43aa-4846-8cb2-c037c5a60e80" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab13e032-3368-44cd-85e6-ebb48d26940c" xlink:to="loc_dei_LocalPhoneNumber_36d58dbb-43aa-4846-8cb2-c037c5a60e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_926610a9-fc81-45a7-b2a3-7adc377f6f86" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab13e032-3368-44cd-85e6-ebb48d26940c" xlink:to="loc_dei_WrittenCommunications_926610a9-fc81-45a7-b2a3-7adc377f6f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_f2eba66b-966f-4504-9a0e-21bf3cdeff26" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab13e032-3368-44cd-85e6-ebb48d26940c" xlink:to="loc_dei_SolicitingMaterial_f2eba66b-966f-4504-9a0e-21bf3cdeff26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_32488ea5-30ea-4eb4-89cc-2fe2543e7edc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab13e032-3368-44cd-85e6-ebb48d26940c" xlink:to="loc_dei_PreCommencementTenderOffer_32488ea5-30ea-4eb4-89cc-2fe2543e7edc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_665a5bd4-6dc2-4bab-932b-ffd337d3bf0e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab13e032-3368-44cd-85e6-ebb48d26940c" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_665a5bd4-6dc2-4bab-932b-ffd337d3bf0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_290003fb-215a-49b0-ba0c-dc8f875323d2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab13e032-3368-44cd-85e6-ebb48d26940c" xlink:to="loc_dei_Security12bTitle_290003fb-215a-49b0-ba0c-dc8f875323d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_276b5928-38ae-47fa-8a28-65eaf1d94dd2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab13e032-3368-44cd-85e6-ebb48d26940c" xlink:to="loc_dei_TradingSymbol_276b5928-38ae-47fa-8a28-65eaf1d94dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_e92cb524-40bb-4a39-abc2-b885326d2d6e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab13e032-3368-44cd-85e6-ebb48d26940c" xlink:to="loc_dei_SecurityExchangeName_e92cb524-40bb-4a39-abc2-b885326d2d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_936a8838-80db-4e04-bb1b-106a2cfafd41" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab13e032-3368-44cd-85e6-ebb48d26940c" xlink:to="loc_dei_EntityEmergingGrowthCompany_936a8838-80db-4e04-bb1b-106a2cfafd41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_d44c1c73-e810-4665-9312-554a25a1be9e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab13e032-3368-44cd-85e6-ebb48d26940c" xlink:to="loc_dei_AmendmentFlag_d44c1c73-e810-4665-9312-554a25a1be9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_dc704543-8e4b-4168-b28e-84e6ca3373be" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab13e032-3368-44cd-85e6-ebb48d26940c" xlink:to="loc_dei_EntityCentralIndexKey_dc704543-8e4b-4168-b28e-84e6ca3373be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>logo.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.gif
M1TE&.#EA@ -# 7   "'_"TY%5%-#05!%,BXP P$!   A^00      "P
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MQ"$' ;-E-79&/E157&_%98\ENQCT!2N% -OJI%]7 A]P.N3<.%XD-D($ 7F
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MB6 IYM;"23\1YPK1_\3.Z!,P')@DL&"$#P9ZCZ'=7*2R2BNOQ#++AQ K2"$
MK&*@! ]T<DFZD'#"*2WI6D- *@:B1&A*+36:2+>+[)P3(0;DY*T@"BCX (+Y
M?LRN+I1NFHLD,A55T[,SE^HQ._ZX@8$-'&@R2CV0G#OJNC9;U&V@*RBMCTRC
M)B!@ LQ".VZ^- W]PK*VRFP-)$<]BS2"&[J!P0H)HLHASSNK4HPQ!M@(H308
M+K!0.0)ZM*Q(,F]==*3["+SI. @Z"&$>':!9*QP!;Q"7.O32&B%8W!CR$L_=
M#J(H3!Q&&+<UG>ZK+%6GR*4).R#_I>ZF B+%3ZD'1O IA-JNT.H!IS2+M?^
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ME!:7&!@$/#MTVB8I((W;JH=$^  VJ(#P&YPQ.KX608PID9.^/$B(X#$^VRH
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M@*_I( Y:O!ZYOAI2LJ9 BN:2K,P8&-0Q)T;+0;0TJB)CO&KTH1O(1H880\R
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M_"D/0A0&&PE*4&$(8>=6#/*!*,I+1U.,5.> $S&0[ >5*;PI3G.*FC"^1H4
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M0%S/Q[F=H(3=4;"!_,R133S>CT#&60S6U6CD2AFF0:K%)^6(/V GT9!DFWI
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M8-/IC<(;$7BXF#+A%!0K+O7KIT9U@@3]7JM9 5LV;-BSY;5N?>0;0X5'KR"
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M(BZW@RQ"4 378 3RB"8Z3KXJ!S CH#+^[CK(YRC@R,)VT.=N( <7+Q0!( C
MC;?(:"LX)1AGCY^$* 5,X)/@<960#!Y!;\B0\'?FT5A^!P1.P"+J<F9D8A;3
M*RJ0Z"L@H&SRY#6M_W1=H*,O'M U?:,G2D"H$F.C+,L_4.;!8("]1"KC$D<2
M$\,_591$YNQ"P^<H\*PC0D*WP$I1HJHCMF_P--"[*F<F&\4!+BLL7"KA%NK\
MS&@\H<IT)NHHX*>FON_0C",DBDU+L^9"'K&LXF(D+F8WH0(KHV=H/L,9,4U
MWT(PPA++\*9.T((R!/4I[% J$&#7,B0#%34Q0#1Q .52[V2!5J]^UN0$ 25(
MA'*L&.@OIV[/.'0+=88D;Y4!@J!I2$1,,",W@U%Q7%+#3. (B&6P6D-XFI#(
MV.TV2,\VNF %CN!YC$3'N&5!ADHYJ*A-ZP(#+ !]KC1?UP6"[&7N%O)0"_]N
M9+2&#B# GH;-64&B5*LN4&"B'K+D+#Y@,)!(0?;#)KJ.(XY3#]$B$3K,*3BE
MJRHG$'5F?R(+41B$),PI1D("OX E/NMN7\#3:8A-.,G-O\Y3:SCH/ZL-1FIQ
M/*1/9/!U.>/#OG(%0$]QN5C6&TT.7'JN0RUV4>A#,)Q#3C/5<QB@I$A-+R-J
M3O3%9$%L!\7$5WDM6:\C0S>4'SFB]6:F18JD2JG#9RIB,@I/&XUC]D)N2NC$
MVV!,5W.E@Q@%1*5"+BDJ!8A #TAI6M91,]]M"8.42(GG,]7@$C; !+!*:[IL
M0W75:>&B( CU/EP2:_0U=!UQ7O!/B-QK-H$)+>;_08QDHBHMJ]"0\@L2H:>8
M!HX^@]]6AAAO8'\*3CSFX?%.LT,Y=RZT[V,$;0.7;U(1H^7$3IB:+%&=9E'/
M::,TYQS1XMM@XF;F ]<4P[\@P/CZ%?_8Q;/FB4^"C6*;2C-DP@(H#3#B(P(\
MHP_)2";ZK# DJJ="RRK"*0>BD69 B!<OT$#8TK5JIBNRD4+W-8)P\-IV*3,P
MB1]%9707:%[**C%04.4$5-M$ (K$:00&TUI9!&&@ BQ]MF=2X!*\]1)B0UI2
MR4<W$S-3R;$2  0XX$:B\OT$;( "$7EM=&3[ G]%-X@WQ!O_0M%<MEV"0IX4
MXL4>)&.@JDGLXWXT)@U^_V,M+HJ) (1S:X)$:(1J?TIK&( E\HXF7$2Y #&$
MG$L "S%19%'^:()$$(!"*L+.O!, HBFJ4/#Z;N4F GB&V,(^-M$.6Z]!YZ&]
MO/,1T21^5:PX_F=0(( .'JD_'V8X$V. %,>ZPC#9OFR^^L/PH()L(FR*YN?P
M/)!QE"HA]V(B4F -F#%$N7*0)Q"X1A1'?(,"*LP.^S#QI'-*BJ@"1J!+<"KE
M"D![M8(&1ZQ" <"3H&4=6ZE<9T/SB!25H/EXVNUW-L .;,\W&$ P-J.2_9 _
MX'=18B^+2&A+A?B<B4+PQ".,FW<^0<M"!'9/)  P 9!HQ^T!'& J4(1;N"E^
MJ=6+U2KG>@H  S  .4-K::@U7)+C+EZD*?A)NTIFAV!/[YRB_RRU KH-H=("
M^33#NR9U;1:&?2WB71'Q*<34H4I"!+K-G1.8+Z2R([.G+>OJ/C#LE[3Y"AC%
M+<!&W!9@ ?X3 [C' 3'D ^"/5X'D0W2M0'"U+0/5@HFVV)SN5NM2WTPP9QYX
M)([5]N0S62>B@FO".?6T,$*.)//D*'*@AKJ9FI WEBU5 N8L2QYV(5#@")[%
M-@B+E9*'<8W,"=EM=U"8<KLGC"4  V!G>:EH93KE!C88(='_N;%]*BW20 ,L
M8/$JY(@S]2Q0I<9.QI[')8D>P!\FA',8@&!! LR8;7BWF'::-\MZSXXUHH(8
M)3H+HNM<9HMB)46*\D&H"7N:(FGAJ6HC(V8!NF$V0X<B1EO<]Q]W$"KJ DP*
M9ND86YA #2>0R(Q>HH-8Y";DT@49X -4)7M![&E0%>"DLXM)#@*5@K U<:(C
M"I39KH+B8G/Y VR,$9F1%0#N3E)CCY>6@FU;4T,XY)!0U&A4C$6#T',"HSG#
M,5=BRS\49ZI&8[0 P X^:7<^\]T4MW&5\+ Z;P7T +("6XIRL'4QB?5@9("
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M1 E*FMVQPA%'4S@%^'>#!'4^QX (%J@E\GL&82 <P"PN-IY#]M*%\5S>O*4
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MI5,"3L,2.V>GX,@G4TIC9K0E9:D=X)%M?!(<;B2%]M%Q0W:$._(>@"DG"(0
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MAP_H +((NBK[P-72+K+ D0Q<M 7(1-6ZPVD*#7ZP@F[PP*20D[1@B'P"KXT
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M#@0%/@.##"(P@3J0CR[(!P[H!PZ0T0F[/N>CL'<]*0,ID.FCT1RJO@K;  X
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M /\;<J"2; 64/I_=K!"?&1%Z3N1-.:B RCY@W ]HX+C&K6T:^N>7!NXN(D3
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MS1% 2BG&>?"&1"I$?A'F<OY%A.@,B02)CE@'&]!'C]Z8?J9JL1KKL2+KF#(
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M30S0[!8(3Q;#3T*BPV)/(31C?Z $4+JM>FP.9GJE9_KC:_2@.^S-?18"04!
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M!A^_#]-<A9BPT!OM0#UD[XPZR>]B8RH9 \[,)N1$(I=FPVI.XVA(0#.Z8,[
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AW=5?'=9C7=9GG=9KW=9O'==S7==WG==[W==_/7 " @ [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139836473613552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page Cover Page<br></strong></div></th>
<th class="th"><div>Apr. 26, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr. 26,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SANGAMO THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">68-0359556<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7000 Marina Blvd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Brisbane<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">970-6000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.01 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SGMO<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001001233<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>sgmo-20230426_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="sgmo-20230426.xsd" xlink:type="simple"/>
    <context id="i2ef6b1eb8e4449539b132b573bb052e5_D20230426-20230426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2023-04-26</startDate>
            <endDate>2023-04-26</endDate>
        </period>
    </context>
    <dei:DocumentPeriodEndDate
      contextRef="i2ef6b1eb8e4449539b132b573bb052e5_D20230426-20230426"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1ZWQxNGVmYmEwNzQ4NDhhZDQ2YzQ4YjA4YzVjN2Q1L3NlYzo0NWVkMTRlZmJhMDc0ODQ4YWQ0NmM0OGIwOGM1YzdkNV80L2ZyYWc6NmM4NWRhOTUzNGQ3NGZjYjllODQwMmExOGExM2NmNjcvdGFibGU6MTU4Mzg3NTEzNWI0NDY0NDhkNTYwZmQxNzNlMTM3YzcvdGFibGVyYW5nZToxNTgzODc1MTM1YjQ0NjQ0OGQ1NjBmZDE3M2UxMzdjN18yLTEtMS0xLTc2NTc0_cc3b0c1a-cba3-43aa-ae5f-21fb4288f5b1">2023-04-26</dei:DocumentPeriodEndDate>
    <dei:EntityCentralIndexKey
      contextRef="i2ef6b1eb8e4449539b132b573bb052e5_D20230426-20230426"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1ZWQxNGVmYmEwNzQ4NDhhZDQ2YzQ4YjA4YzVjN2Q1L3NlYzo0NWVkMTRlZmJhMDc0ODQ4YWQ0NmM0OGIwOGM1YzdkNV80L2ZyYWc6NmM4NWRhOTUzNGQ3NGZjYjllODQwMmExOGExM2NmNjcvdGFibGU6MTU4Mzg3NTEzNWI0NDY0NDhkNTYwZmQxNzNlMTM3YzcvdGFibGVyYW5nZToxNTgzODc1MTM1YjQ0NjQ0OGQ1NjBmZDE3M2UxMzdjN18zLTEtMS0xLTc2NTc0_8be7ec93-f4c7-4304-8944-2b7107389728">0001001233</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i2ef6b1eb8e4449539b132b573bb052e5_D20230426-20230426"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1ZWQxNGVmYmEwNzQ4NDhhZDQ2YzQ4YjA4YzVjN2Q1L3NlYzo0NWVkMTRlZmJhMDc0ODQ4YWQ0NmM0OGIwOGM1YzdkNV80L2ZyYWc6NmM4NWRhOTUzNGQ3NGZjYjllODQwMmExOGExM2NmNjcvdGFibGU6MTU4Mzg3NTEzNWI0NDY0NDhkNTYwZmQxNzNlMTM3YzcvdGFibGVyYW5nZToxNTgzODc1MTM1YjQ0NjQ0OGQ1NjBmZDE3M2UxMzdjN180LTEtMS0xLTc2NTc0_b1039171-fdb3-4557-a0f0-0d8d129971ec">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i2ef6b1eb8e4449539b132b573bb052e5_D20230426-20230426"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1ZWQxNGVmYmEwNzQ4NDhhZDQ2YzQ4YjA4YzVjN2Q1L3NlYzo0NWVkMTRlZmJhMDc0ODQ4YWQ0NmM0OGIwOGM1YzdkNV8xL2ZyYWc6NjBhMTExMmRiOWViNDcyZGIwODI4NDdiZWI0YmZmNTAvdGV4dHJlZ2lvbjo2MGExMTEyZGI5ZWI0NzJkYjA4Mjg0N2JlYjRiZmY1MF84Ng_ab92034e-53af-4768-8c2f-1990bba5c57e">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i2ef6b1eb8e4449539b132b573bb052e5_D20230426-20230426"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1ZWQxNGVmYmEwNzQ4NDhhZDQ2YzQ4YjA4YzVjN2Q1L3NlYzo0NWVkMTRlZmJhMDc0ODQ4YWQ0NmM0OGIwOGM1YzdkNV8xL2ZyYWc6NjBhMTExMmRiOWViNDcyZGIwODI4NDdiZWI0YmZmNTAvdGV4dHJlZ2lvbjo2MGExMTEyZGI5ZWI0NzJkYjA4Mjg0N2JlYjRiZmY1MF8yMzA_cc3b0c1a-cba3-43aa-ae5f-21fb4288f5b1">2023-04-26</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i2ef6b1eb8e4449539b132b573bb052e5_D20230426-20230426"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1ZWQxNGVmYmEwNzQ4NDhhZDQ2YzQ4YjA4YzVjN2Q1L3NlYzo0NWVkMTRlZmJhMDc0ODQ4YWQ0NmM0OGIwOGM1YzdkNV8xL2ZyYWc6NjBhMTExMmRiOWViNDcyZGIwODI4NDdiZWI0YmZmNTAvdGV4dHJlZ2lvbjo2MGExMTEyZGI5ZWI0NzJkYjA4Mjg0N2JlYjRiZmY1MF8yMzc_df36b70e-615e-4128-aceb-0dab29fb4207">SANGAMO THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i2ef6b1eb8e4449539b132b573bb052e5_D20230426-20230426"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1ZWQxNGVmYmEwNzQ4NDhhZDQ2YzQ4YjA4YzVjN2Q1L3NlYzo0NWVkMTRlZmJhMDc0ODQ4YWQ0NmM0OGIwOGM1YzdkNV8xL2ZyYWc6NjBhMTExMmRiOWViNDcyZGIwODI4NDdiZWI0YmZmNTAvdGFibGU6OWU3NzA0MmEyNDQ0NGU3NmI4MTRlODU4M2MxMzBkNjAvdGFibGVyYW5nZTo5ZTc3MDQyYTI0NDQ0ZTc2YjgxNGU4NTgzYzEzMGQ2MF8xLTAtMS0xLTc2NTc0_ae0b99fb-245a-4b98-bac3-02121299a665">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i2ef6b1eb8e4449539b132b573bb052e5_D20230426-20230426"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1ZWQxNGVmYmEwNzQ4NDhhZDQ2YzQ4YjA4YzVjN2Q1L3NlYzo0NWVkMTRlZmJhMDc0ODQ4YWQ0NmM0OGIwOGM1YzdkNV8xL2ZyYWc6NjBhMTExMmRiOWViNDcyZGIwODI4NDdiZWI0YmZmNTAvdGFibGU6OWU3NzA0MmEyNDQ0NGU3NmI4MTRlODU4M2MxMzBkNjAvdGFibGVyYW5nZTo5ZTc3MDQyYTI0NDQ0ZTc2YjgxNGU4NTgzYzEzMGQ2MF8xLTItMS0xLTc2NTc0_4c977872-3021-4aed-96cb-9cba7f8571cf">000-30171</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i2ef6b1eb8e4449539b132b573bb052e5_D20230426-20230426"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1ZWQxNGVmYmEwNzQ4NDhhZDQ2YzQ4YjA4YzVjN2Q1L3NlYzo0NWVkMTRlZmJhMDc0ODQ4YWQ0NmM0OGIwOGM1YzdkNV8xL2ZyYWc6NjBhMTExMmRiOWViNDcyZGIwODI4NDdiZWI0YmZmNTAvdGFibGU6OWU3NzA0MmEyNDQ0NGU3NmI4MTRlODU4M2MxMzBkNjAvdGFibGVyYW5nZTo5ZTc3MDQyYTI0NDQ0ZTc2YjgxNGU4NTgzYzEzMGQ2MF8xLTQtMS0xLTc2NTc0_acbff352-3821-43ff-a437-3e7f0a1635ca">68-0359556</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i2ef6b1eb8e4449539b132b573bb052e5_D20230426-20230426"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1ZWQxNGVmYmEwNzQ4NDhhZDQ2YzQ4YjA4YzVjN2Q1L3NlYzo0NWVkMTRlZmJhMDc0ODQ4YWQ0NmM0OGIwOGM1YzdkNV8xL2ZyYWc6NjBhMTExMmRiOWViNDcyZGIwODI4NDdiZWI0YmZmNTAvdGV4dHJlZ2lvbjo2MGExMTEyZGI5ZWI0NzJkYjA4Mjg0N2JlYjRiZmY1MF8yNTkx_5f1c276a-a704-4265-8d5d-42ac383e2263">7000 Marina Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i2ef6b1eb8e4449539b132b573bb052e5_D20230426-20230426"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1ZWQxNGVmYmEwNzQ4NDhhZDQ2YzQ4YjA4YzVjN2Q1L3NlYzo0NWVkMTRlZmJhMDc0ODQ4YWQ0NmM0OGIwOGM1YzdkNV8xL2ZyYWc6NjBhMTExMmRiOWViNDcyZGIwODI4NDdiZWI0YmZmNTAvdGV4dHJlZ2lvbjo2MGExMTEyZGI5ZWI0NzJkYjA4Mjg0N2JlYjRiZmY1MF8yNTky_402948c4-85b1-4447-9221-d34e9c4cbd5b">Brisbane</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i2ef6b1eb8e4449539b132b573bb052e5_D20230426-20230426"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1ZWQxNGVmYmEwNzQ4NDhhZDQ2YzQ4YjA4YzVjN2Q1L3NlYzo0NWVkMTRlZmJhMDc0ODQ4YWQ0NmM0OGIwOGM1YzdkNV8xL2ZyYWc6NjBhMTExMmRiOWViNDcyZGIwODI4NDdiZWI0YmZmNTAvdGV4dHJlZ2lvbjo2MGExMTEyZGI5ZWI0NzJkYjA4Mjg0N2JlYjRiZmY1MF8zMjk_66564950-0896-43f7-ab16-aef097b788f3">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i2ef6b1eb8e4449539b132b573bb052e5_D20230426-20230426"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1ZWQxNGVmYmEwNzQ4NDhhZDQ2YzQ4YjA4YzVjN2Q1L3NlYzo0NWVkMTRlZmJhMDc0ODQ4YWQ0NmM0OGIwOGM1YzdkNV8xL2ZyYWc6NjBhMTExMmRiOWViNDcyZGIwODI4NDdiZWI0YmZmNTAvdGV4dHJlZ2lvbjo2MGExMTEyZGI5ZWI0NzJkYjA4Mjg0N2JlYjRiZmY1MF8yNTkz_42b67ebf-b6a0-4f46-b68e-4282c724dc52">94005</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i2ef6b1eb8e4449539b132b573bb052e5_D20230426-20230426"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1ZWQxNGVmYmEwNzQ4NDhhZDQ2YzQ4YjA4YzVjN2Q1L3NlYzo0NWVkMTRlZmJhMDc0ODQ4YWQ0NmM0OGIwOGM1YzdkNV8xL2ZyYWc6NjBhMTExMmRiOWViNDcyZGIwODI4NDdiZWI0YmZmNTAvdGV4dHJlZ2lvbjo2MGExMTEyZGI5ZWI0NzJkYjA4Mjg0N2JlYjRiZmY1MF8zOTI_21d6ea38-d4af-4afc-915e-e0a939cfea0d">510</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i2ef6b1eb8e4449539b132b573bb052e5_D20230426-20230426"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1ZWQxNGVmYmEwNzQ4NDhhZDQ2YzQ4YjA4YzVjN2Q1L3NlYzo0NWVkMTRlZmJhMDc0ODQ4YWQ0NmM0OGIwOGM1YzdkNV8xL2ZyYWc6NjBhMTExMmRiOWViNDcyZGIwODI4NDdiZWI0YmZmNTAvdGV4dHJlZ2lvbjo2MGExMTEyZGI5ZWI0NzJkYjA4Mjg0N2JlYjRiZmY1MF8zOTY_203556b1-9b99-45e1-94b0-bb513e081f8a">970-6000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="i2ef6b1eb8e4449539b132b573bb052e5_D20230426-20230426"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1ZWQxNGVmYmEwNzQ4NDhhZDQ2YzQ4YjA4YzVjN2Q1L3NlYzo0NWVkMTRlZmJhMDc0ODQ4YWQ0NmM0OGIwOGM1YzdkNV8xL2ZyYWc6NjBhMTExMmRiOWViNDcyZGIwODI4NDdiZWI0YmZmNTAvdGFibGU6N2NlZTRiNGMzZGUwNDMzMmEwNjJlYjRhMzYwMjU2NzgvdGFibGVyYW5nZTo3Y2VlNGI0YzNkZTA0MzMyYTA2MmViNGEzNjAyNTY3OF8wLTAtMS0xLTc2NTc0_65c6df50-2516-48a8-835c-3b571bf6c60a">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i2ef6b1eb8e4449539b132b573bb052e5_D20230426-20230426"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1ZWQxNGVmYmEwNzQ4NDhhZDQ2YzQ4YjA4YzVjN2Q1L3NlYzo0NWVkMTRlZmJhMDc0ODQ4YWQ0NmM0OGIwOGM1YzdkNV8xL2ZyYWc6NjBhMTExMmRiOWViNDcyZGIwODI4NDdiZWI0YmZmNTAvdGFibGU6YWVjOGZkYjRiNTEyNGEzZjk5OGNlOTU5MjQ1ZmNmZWQvdGFibGVyYW5nZTphZWM4ZmRiNGI1MTI0YTNmOTk4Y2U5NTkyNDVmY2ZlZF8wLTAtMS0xLTc2NTc0_f078855f-05f6-4a3d-acb8-a4bd43a93e9d">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i2ef6b1eb8e4449539b132b573bb052e5_D20230426-20230426"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1ZWQxNGVmYmEwNzQ4NDhhZDQ2YzQ4YjA4YzVjN2Q1L3NlYzo0NWVkMTRlZmJhMDc0ODQ4YWQ0NmM0OGIwOGM1YzdkNV8xL2ZyYWc6NjBhMTExMmRiOWViNDcyZGIwODI4NDdiZWI0YmZmNTAvdGFibGU6ZDRhZDgyNjg3YWRlNDZhNzg4OGFiYmNiOGRlODQ0NGMvdGFibGVyYW5nZTpkNGFkODI2ODdhZGU0NmE3ODg4YWJiY2I4ZGU4NDQ0Y18wLTAtMS0xLTc2NTc0_9b4766bf-b5e3-4361-ab68-6111297cc7d8">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i2ef6b1eb8e4449539b132b573bb052e5_D20230426-20230426"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1ZWQxNGVmYmEwNzQ4NDhhZDQ2YzQ4YjA4YzVjN2Q1L3NlYzo0NWVkMTRlZmJhMDc0ODQ4YWQ0NmM0OGIwOGM1YzdkNV8xL2ZyYWc6NjBhMTExMmRiOWViNDcyZGIwODI4NDdiZWI0YmZmNTAvdGFibGU6OGMzNDNiZGU5NDhhNDBkZWFjNzI3MmQ4N2UzOGRhNjkvdGFibGVyYW5nZTo4YzM0M2JkZTk0OGE0MGRlYWM3MjcyZDg3ZTM4ZGE2OV8wLTAtMS0xLTc2NTc0_5949e3ef-eaaa-449f-b5cb-56c288d7bf6e">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="i2ef6b1eb8e4449539b132b573bb052e5_D20230426-20230426"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1ZWQxNGVmYmEwNzQ4NDhhZDQ2YzQ4YjA4YzVjN2Q1L3NlYzo0NWVkMTRlZmJhMDc0ODQ4YWQ0NmM0OGIwOGM1YzdkNV8xL2ZyYWc6NjBhMTExMmRiOWViNDcyZGIwODI4NDdiZWI0YmZmNTAvdGFibGU6MTE2Y2FjNmVlNDZjNDE0NGFhODZhMDcxMzg5ZmQzMzUvdGFibGVyYW5nZToxMTZjYWM2ZWU0NmM0MTQ0YWE4NmEwNzEzODlmZDMzNV8yLTAtMS0xLTc2NTc0_769a715d-a035-401f-946e-0c9ccaead85c">Common Stock, $0.01 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i2ef6b1eb8e4449539b132b573bb052e5_D20230426-20230426"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1ZWQxNGVmYmEwNzQ4NDhhZDQ2YzQ4YjA4YzVjN2Q1L3NlYzo0NWVkMTRlZmJhMDc0ODQ4YWQ0NmM0OGIwOGM1YzdkNV8xL2ZyYWc6NjBhMTExMmRiOWViNDcyZGIwODI4NDdiZWI0YmZmNTAvdGFibGU6MTE2Y2FjNmVlNDZjNDE0NGFhODZhMDcxMzg5ZmQzMzUvdGFibGVyYW5nZToxMTZjYWM2ZWU0NmM0MTQ0YWE4NmEwNzEzODlmZDMzNV8yLTItMS0xLTc2NTc0_6afa7108-1c80-4612-99a9-3978666afea8">SGMO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i2ef6b1eb8e4449539b132b573bb052e5_D20230426-20230426"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1ZWQxNGVmYmEwNzQ4NDhhZDQ2YzQ4YjA4YzVjN2Q1L3NlYzo0NWVkMTRlZmJhMDc0ODQ4YWQ0NmM0OGIwOGM1YzdkNV8xL2ZyYWc6NjBhMTExMmRiOWViNDcyZGIwODI4NDdiZWI0YmZmNTAvdGFibGU6MTE2Y2FjNmVlNDZjNDE0NGFhODZhMDcxMzg5ZmQzMzUvdGFibGVyYW5nZToxMTZjYWM2ZWU0NmM0MTQ0YWE4NmEwNzEzODlmZDMzNV8yLTQtMS0xLTc2NTc0_30713595-e08d-462b-8191-7c944df41bfd">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="i2ef6b1eb8e4449539b132b573bb052e5_D20230426-20230426"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1ZWQxNGVmYmEwNzQ4NDhhZDQ2YzQ4YjA4YzVjN2Q1L3NlYzo0NWVkMTRlZmJhMDc0ODQ4YWQ0NmM0OGIwOGM1YzdkNV8xL2ZyYWc6NjBhMTExMmRiOWViNDcyZGIwODI4NDdiZWI0YmZmNTAvdGV4dHJlZ2lvbjo2MGExMTEyZGI5ZWI0NzJkYjA4Mjg0N2JlYjRiZmY1MF8xMDQz_a51f92be-525b-4cd7-8772-83c2fd635c8e">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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ML0(  .(,   -    >&PO<W1Y;&5S+GAM;-U7;6O;,!#^*T(_8&YB:N*1&+9
M8;"-0O-A7Y58=@1Z\62Y<_KKI[-L)VEU9=V'L<VAR=T]NKM'=R>9KEMWDOSA
MR+DCO9*ZW="C<\W[)&D/1ZY8^\XT7'ND,E8QYU5;)VUC.2M;<%(R6=[<9(EB
M0M-BK3MUIUQ+#J;3;D-O:%*L*Z//EI0&@U_*%">/3&[HEDFQMV)8RY20IV!>
M@N%@I+'$>2I\0Q=@:9\"O @:L!SC**&-!6,2,H3O_;C\&3!IK5>%E#/!)0V&
M8MTPY[C5=UX9%@_&%Q 9Y=VI\0QKRTZ+Y2T].PP_/LG>V)+;.<V"3J9B+7D%
M=*RHC_#K3), Z)Q17B@%JXUF X?)8Q1\V .7\@%:^*VZBMU7)/3B4PEM(+#5
M2?2$1C&$"0K$OXP68E^$O?VML*01C\9][/QN]*!_[XSC]Y97HA_TOIKS8]$7
M>'36-/+T08I:*Q[V_LL)BS6;_,C16/'DL\&D'+R!6TH>N77B<&GY85FSX[V;
MIJFO<,[+?Y#SGZUSS36W3%Z2]J/_-U?Y+8R3\?1<'-&K SI;"5R$&_H5[E=Y
MYD#VG9!.Z%$[BK+D^L4Y]>$=V_L+_"J^7U_RBG72[69P0\_R%UZ*3N7SJGNH
MR[CJ+'^&^VB1S;>PSR5TR7M>;D?5UOM!)%[P6<<'')XC=\,31S"?@,41P+ \
M& /,)WAA>?ZG_:S0_00,X[:*(BO49X7Z!*\8LAT^6)ZX3^Z?^$[S/$VS#*OH
M=AMEL,7JEF7P%X^&<0,/+ ]D>ENM\6[C$_+Z'& ]?6U"L)WBDXCM%*\U(/&Z
M@4>>Q[N-Y0$/K O8[$#^>!Z8J;A/FD)7,6[8"<:1/,<0F,7XC&894IT,/O'^
M8*<D3?,\C@ 69Y"F& *G$4<P!L !0])T> \^>Q\ETWLJ.?]74_P$4$L#!!0
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MU\7!ZQ^4ZD2HN7/08&<B+EA0BJN$7/D=<.I[.T!*1D.QD8E>I6.5Z*U .EK
M>MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*$3FQ
M!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87_QO.
M\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0    ( -"*FE8'04UB@0   +$
M   0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%
M  @ T(J:5FS0PPGN    *P(  !$              ( !KP   &1O8U!R;W!S
M+V-O<F4N>&UL4$L! A0#%     @ T(J:5IE<G",0!@  G"<  !,
M     ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " #0BII6
MAB:YU5,$  "/$   &               @($-"   >&PO=V]R:W-H965T<R]S
M:&5E=#$N>&UL4$L! A0#%     @ T(J:5I^@&_"Q @  X@P   T
M     ( !E@P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #0BII6EXJ[',
M   3 @  "P              @ %R#P  7W)E;',O+G)E;'-02P$"% ,4
M" #0BII6Y6B*[#D!   R @  #P              @ %;$   >&PO=V]R:V)O
M;VLN>&UL4$L! A0#%     @ T(J:5B0>FZ*M    ^ $  !H
M ( !P1$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @
MT(J:5F60>9(9 0  SP,  !,              ( !IA(  %M#;VYT96YT7U1Y
><&5S72YX;6Q02P4&      D "0 ^ @  \!,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="sgmo-20230426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CoverPageCoverPage</Role>
      <ShortName>Cover Page Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:DocumentPeriodEndDate -  sgmo-20230426.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="8-K" original="sgmo-20230426.htm">sgmo-20230426.htm</File>
    <File>exhibit-99120230426.htm</File>
    <File>sgmo-20230426.xsd</File>
    <File>sgmo-20230426_lab.xml</File>
    <File>sgmo-20230426_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "sgmo-20230426.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 23
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "sgmo-20230426.htm"
     ]
    },
    "labelLink": {
     "local": [
      "sgmo-20230426_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sgmo-20230426_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "sgmo-20230426.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "sgmo",
   "nsuri": "http://www.sangamo.com/20230426",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230426.htm",
      "contextRef": "i2ef6b1eb8e4449539b132b573bb052e5_D20230426-20230426",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.sangamo.com/role/CoverPageCoverPage",
     "shortName": "Cover Page Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230426.htm",
      "contextRef": "i2ef6b1eb8e4449539b132b573bb052e5_D20230426-20230426",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001628280-23-013290-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-23-013290-xbrl.zip
M4$L#!!0    ( -"*FE:$&:MKVB(  (&Y   7    97AH:6)I="TY.3$R,#(S
M,#0R-BYH=&WM7>ES&[FQ__[^"L2[V>Q6D=1I^8RK:!VV-K:L2'+VY7UY!<Z
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M#+]/)-!7%F*8R%$QUA,QR<THERFRRFQLDF0NS"R#,>E+8.;G0DWT2&4*[+<
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M V2 __+FN<0EI"EIAP'@N[&"5\6HQ9%6/?&+ JL>1< XPPJQ06P!IVJ!3L(
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M^&/#^FL0Q/\WCFO<R=[7,IHU-#XXE*E9,K\/^]GC/9G=?L)W0D&Y6);2!>H
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M9AA]Q4]:G7I\NGO0@HI2XW%*/D^^7%5M?5,N/K]O55:V*T7E(MXE)U_,1%R
M%]@<ZJ^"#@#&#,%&PK>(59$.SK2%W6'LDR.P,L"0BE6]W;JP0Y!KIA.VR[&%
MRKDNKET7'_LW*B7T4\'6+3K"DF%J:XT>#\SE!&:$EF.A(PQR3- D"?O <[\F
M;W<'5;U&LKU65%;-I-D_#-Z?NDZV=2>#(FAR[7NYA,;:]TC"#5K:1:ENPVVE
M/#4H4T2B<HR,V_'7OF/W-%9SJ_O'< .UNFL:RV[[>:=",3[[1445\@]ZD'<6
M8ZR[JQU$1%%XH3MN&+^0E#73Q MD2_ZX75$XYD#A3WO1#?6B"O4=LC(U6RI<
MA!I&K%+KOV*%*?FXS<X4=W\Y\@8)W*T[)J,QELVZKA>JI6>H[I6<OT;9:^MM
MW G=W9SH%.""-N#)5*!H2P9SV+P)?'0^R/:&KCDX28?M*-)>ASM_JLF$J301
M%P:E,LH-]L*E,,/0"AML?,!?8XFWS8^:I7^R6"CQ=\@,U0_ <^PO5,X ZHF+
M"@R6I!WX?)U+CT4./_WC]*B[\P*T&JPT=<#4PFT$1&U4,<!DY2$@ FX/:&.B
M(\X(\@=M*IN"%<\8HXSK+ B^6Y1%/ZA/;506WP9AVST)N=>8%QD_$O4_;.+*
MF@!U,WV$O<'U2+9'V$+C0\+)O)[Z#?CE31+V>G<BO*>_&K3_6N;*V'9F#?S;
M\&EJ%F-EL&0DO#@5]K;#-[GRN&.3Q*106X_6GEW38W1&@OOXM!R&>@YU"SV+
M[-GF6MM.H?=,EK8A4.O5=B?:DH"VF[5=Z,\ZA793,WD*^]NN9V GW;&:]S9E
MP5<(V1OV&B]:^C(S +)/70]$14X27LH7@($E_N:R*ZX"[[!>;?T5>_T4AKH+
M[2#=XCCG%\>'I_]SUMVQ?M^M"Z918('<6Z_-)8T9MT:<2FXF: ]#ALKZ9@H1
MG(SF-[I[G?K-Q,]A"_XXE[.,7WM\<<4OY.M(8,@A_BWDKI"1@ON%J()TBJC+
M=ESDUL@+CBV:/O@T130V:0U1E6/#O2[XA;Y]'O7H\D+*ES(NQ _"=E@U>@:
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MM]L.&+ZM(Y"M@8GG\)]QF29O_@]02P,$%     @ T(J:5D=0B2)Y'0  =L
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M*>?-[V/$6[$PAQO&R34UKY]+!@8L<Y(/EM*4/.+(-;B:!5%\,LX9OZ;/71C
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MM)3"NTW+*^^;D(OOGBKRN?<M+[ZG/R@ )_5)I_GU?9%>7I4>]"%Z^FGQ2I+
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M65$TO%8H284RB"J4O[0--ND!_YGPEMM8GP%<'>['Y\*XB]./SP;W0N<'>7C
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M3/1( B:O R> '8%MBW^7L;WP+PI:-;O.[^<LGTVKIA.-154!8 QP1"5@$D5
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MM>'SY[2SMH-J;6893%T%_B'C>7&=%W5?_+S4>>,TO\G*XOXT%W+J*QRA"":
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M-BYH=&U02P$"% ,4    " #0BII61U")(GD=  !VP   $0
M@ $/(P  <V=M;RTR,#(S,#0R-BYH=&U02P$"% ,4    " #0BII6[0RD^7("
M  "5!P  $0              @ &W0   <V=M;RTR,#(S,#0R-BYX<V102P$"
M% ,4    " #0BII65[7PM6D*  !$7@  %0              @ %80P  <V=M
M;RTR,#(S,#0R-E]L86(N>&UL4$L! A0#%     @ T(J:5B]D-PVM!@   3$
M !4              ( !]$T  '-G;6\M,C R,S T,C9?<')E+GAM;%!+!08
1    !0 % $D!  #45      !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
